STAAR Surgical Q3 net sales $76M (+30% YoY); ICL units +40%; guides FY22 ~$285M

STAAR SURGICAL CO

2022-Q3 EPS reported $0.67 revenue$220,347,000

Net sales $76.0M, constant currency $80.0M (+37%); ICL sales $72.0M (+33%), ICL units +40%.
GAAP EPS $0.21, adjusted EPS $0.37 vs. $0.12 and $0.21 in prior year quarter.
Gross margin 79.5% vs 77.6%; operating expenses $46.8M vs $37.5M.
FY22 net sales guided to ~$285M (~$300M constant currency); ICL sales ~$272M (+28% YoY).
Other Products to be phased out by end-2023; FY23 net sales target ~$355M with 30% ICL growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

STAAR SURGICAL CO reported the third quarter ended September 30, 2022 results: revenue $76.0 million, net income $10.3 million or $0.21 per diluted share, EPS $0.21 per diluted share. Guidance reaffirmed.

Period: the third quarter ended September 30, 2022
Revenue: $76.0 million
Net income: $10.3 million or $0.21 per diluted share
EPS: $0.21 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

STAAR Surgical Reports Third Quarter Net Sales of $76 Million Up 30% Y/Y

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

STAAR SURGICAL CO filing history →

Source: SEC EDGAR

accession 0001564590-22-036358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.